Arecor

Advanced delivery of biologics

News & Events

Stay up to date: Sign up for email Join us on LinkedIN Follow us on Twitter


Arecor has been selected to appear in the 2016/17 edition of The Parliamentary Review

The Company features alongside The Prime Minister, The Rt Hon Theresa May MP, and a small number of outstanding organisations in the Technology edition

Read more


Arecor Announces License Agreement with Global Pharmaceutical Company

This is the first license conversion resulting from the multi-product Research Agreement entered in to by both parties at the end of 2015.

Read more


Arecor announces the inaugural formation of a global diabetes Scientific Advisory Board

Constituting our SAB is an important step in helping to drive forward our diabetes product development plans and we are delighted to have brought together such eminent thought leaders in the field

Read more


Arecor Appoints Sam Fazeli to Board as Non-Executive Director

We are delighted to welcome Sam to the Board. He brings with him a global perspective across biologics and pharmaceuticals, which will deliver valuable insights for Arecor as we accelerate our dual...

Read more


Charty Cycle Ride

Arecor celebrates 10 years by Cycling for Charity

Read more


Presentation by Arecor at BioTrinity 2017

A copy of Dr Sarah Howell, CEO’s presentation at BioEurope 2017, which she gave on Tuesday, 9 May 2017 is now available on the following link.

Read more


Arecor's CEO discusses the company's innovative formulation technology platform and its partnership with the London Stock Exchange's ELITE programme for growth companies

A recent interview between Dr Sarah Howell, Chief Executive Officer of Arecor and Zarina Nasib, UK Manager of the London Stock Exchange’s ELITE Programme for growth companies.

Read more


Arecor to present at BioTrinity

Dr Sarah Howell, CEO will be presenting at BioTrinity 2017

Read more


Arecor's diabetes partnership with Cadila Pharmaceuticals of India

Arecor's partnership highlighted during Philip Hammond's visit to Delhi and Mumbai

Read more


How we love those EUREKA! moments! (Cambridge Business Magazine - April 2017)

Arecor is one of those Cambridge 'jewels'....

Read more


Arecor to present at the 7th Annual Cell Culture & Downstream World Congress

Dr Jan Jezek, CSO to present

Read more


ARECOR AWARDED £1.05M FROM INNOVATE UK TO SUPPORT THE ADVANCEMENT OF ITS DIABETES GLUCAGON PRODUCT TOWARDS CLINICAL TRIALS

Partnership with Innovate UK to accelerate pre-clinical asset towards proof-of-concept & first-in-human trials

Read more


JDRF Announces Partnership with Arecor Ltd

JDRF Announces Partnership with Arecor Ltd to Support Development of a Stable, Rapid-Acting, Ultra-Concentrated Insulin

Read more


Arecor awarded Innovate UK proof of concept SMART Grant to investigate longer acting basal insulin formulation

Arecor awarded Innovate UK proof of concept SMART Grant to investigate longer acting basal insulin formulation

Read more


Arecor, CPI and FUJIFILM Diosynth Biotechnologies collaborate

Arecor, CPI and FUJIFILM Diosynth Biotechnologies collaborate to apply smart formulation approaches in the manufacturing of biopharmaceuticals under a grant awarded by Innovate UK

Read more


Thomas Saylor Announcement of Resignation

Tom Saylor is retiring as CEO of Arecor, the position in which he has effectively served for the past 8 years.

Read more


FluGen-Arecor Partnership successfully completes Innovate UK SMART Grant funded project to develop stable liquid formulations of promising Universal Flu Vaccine REDEE FLU™

FluGen-Arecor Partnership successfully completes Innovate UK SMART Grant funded project to develop stable liquid formulations of promising Universal Flu Vaccine REDEE FLU™

Read more


ARECOR awarded TSB Grant to Support Expanded Protein Stability Platform

Arecor Limited was awarded a prestigious Technology Strategy Board (TSB) grant to apply its proprietary technology for developing stable formulations of protein drugs

Read more


GALVmed and Arecor Collaborate to Pursue New Vaccine Formulations for Developing World Livestock

New vaccine formulations to combat two major diseases of livestock in the developing world are to be pursued through a partnership between GALVmed and Arecor

Read more


CPI Collaborate With Arecor To Enhance The Compatibility Of Biologic Medicines With Containers

The Centre for Process Innovation is working with Arecor to enhance the compatibility of biologic medicines with containers, and so improving stability and shelf life during transportation and storage

Read more


Arecor Featured in GEN: Arecor Employs Excipients for Biologics Stability

Arecor are the latest company to be profiled by GEN Magazine

Read more


Arecor present data showing Arestat™ formulation technology significantly improves temperature stability for major vaccine types

Arecor present data showing Arestat™ formulation technology significantly improves temperature stability for major vaccine types at 14th World Vaccine Congress

Read more


Arecor Featured in Start-Up Magazine

Arecor were featured in the February edition of Start-Up magazine. It featured a summary of our business model and reviewed some of our recent successes.

Read more


A New Year Message From Arecor

Arecor CEO Thomas Saylor's Message for the New Year

Read more


ARECOR LAUNCHES NEW PLATFORM TOOL FOR VISCOSITY REDUCTION IN HIGH CONCENTRATION BIOLOGICS

Arecor creates a novel proprietary formulation design tool to reduce the viscosity of liquid biologic formulations.

Read more


Government support for innovation and the Cambridge story – with the Rt Hon Sir James Paice MP

Sir Jim Paice MP’s roundtable discussion with Cambridge biotech stakeholders.

Read more


FluGen-Arecor Partnership Enhances Promise of Universal Flu Vaccine Through Funding Award from the UK’s Innovation Agency, the Technology Strategy Board

Arecor Ltd received the “green light” and funding to pursue a research project applying Arecor’s innovative Arestat™ formulation technology to a promising flu vaccine, REDEE FLU™, developed by FluGen.

Read more


ARECOR GRANTED KEY US PATENT FOR METALLOPROTEIN STABILISATION

Arecor announced today the granting of US Patent No. 8486388, to enable stable ready-to-use liquid formulations of metalloproteins such as blood coagulation medicines.

Read more


ARECOR PATENTS GROUND BREAKING HEAT STABLE ADENOVIRUS VACCINE TECHNOLOGY

Arecor announces today a significant leap forward to enabling liquid-stable versions of live-virus containing products, used widely in vaccines and gene therapy products.

Read more


Science Minister David Willetts visits Arecor

Science Minister David Willetts today visited Arecor to learn more about its pioneering projects after being awarded £785,000 under the government-backed Biomedical Catalyst.

Read more


DSM Venturing invests in Arecor innovative protein stabilization technology

DSM Venturing, the corporate venture arm of Royal DSM, the global Life Sciences and Materials Sciences company, announced making a minority investment in Cambridge, UK based Arecor Ltd.

Read more


Arecor’s Director Dr Andy Richards presented with BioIndustry Lifetime Achievement Award

Dr Andy Richards, a member of Arecor’s Board of Directors, has been presented with the distinguished BioIndustry Association (BIA) Lifetime Achievement Award.

Read more


A New Year Message From Arecor

Arecor CEO Thomas Saylor's Message for the New Year

Read more


Arecor presents its unique technology at key life science conferences

Arecor highlighted its unique cutting edge technology at three key conferences this month attended by leading global companies within the life science industry

Read more


Arecor Awarded Biomedical Catalyst Funding Towards £1.3 Million Project

Cambridge biotech company Arecor has been awarded £785,000 from the government-backed Biomedical Catalyst Fund.

Read more


Arecor collaborates in award-winning internship for Cambridge University MBE programme.

Arecor intern Basmah Khogeer wins RSA bioscience excellence award

Read more


Arecor forms collaboration with Lilly to develop advanced formulations of protein therapeutics

Arecor Limited has entered into a collaboration agreement with Eli Lilly and Company to assess Arecor’s advanced protein formulation technologies for possible use with Lilly's products

Read more


Arecor appoints Dr. Sarah Howell as Chief Operating Officer

Arecor, the leading company in advancing aqueous formulation solutions for proteins, peptides and vaccines, is pleased to announce the appointment of Dr Sarah Howell as Chief Operating Officer.

Read more


Arecor and GSK form collaboration to advance new vaccines

Arecor and GSK have entered into a license agreement to develop advanced formulations of vaccines combining Arecor’s unique formulation technologies with GSK’s proprietary vaccines.

Read more


Arecor and Genzyme collaborate to advance protein therapeutics

Arecor and Genzyme form collaboration to advance protein therapeutics

Read more


Hepatitis B vaccine protected against heat and freeze damage

Breakthrough formulation methods, recently published in Human Vaccines and Vaccine, help to stabilize hepatitis B vaccine when temperatures rise and fall

Read more